Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TRVN - TREVENA INC

2.465
-2.560   -103.854%

Share volume: 0
Last Updated: Mon 07 Oct 2024 08:25:42 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): -0.19%

PREVIOUS CLOSE
CHG
CHG%
$5.02
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
7%
Profitability 0%
Dept financing 25%
Liquidity 41%
Performance 1%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
563.64%
1 Year
113.14%
2 Year
-17.98%
Key data
Stock price
$2.46
P/E Ratio 
0.00
DAY RANGE
$2.42 - $5.02
EPS 
$0.00
52 WEEK RANGE
$0.20 - $7.85
52 WEEK CHANGE
$113.14
MARKET CAP 
3.190 M
YIELD 
N/A
SHARES OUTSTANDING 
21.323 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.89
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Carrie L. Bourdow
Region: US
Website: trevena.com
Employees: 40
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Trevena focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain.

Recent news